Parkinson's UK’s Post

Read our new tech note on TL1A:DR3 - A Pathway for Immunomodulation! Learn more about the mechanisms underlying TL1A:DR3 signaling, its physiological roles, and its potential applications in clinical settings. Find novel enabling tools for your TL1A-DR3 drug discovery and contact us today! #TL1A #immunotherapy #drugdiscovery https://hubs.ly/Q02zvNfl0

We are very grateful for the support from the European Commission - European Innovation Council and SMEs Executive Agency (EISMEA)  because is a huge impetus for Integra Therapeutics and our #FiCAT advanced therapies platform. Also, I am pleased to see that 21% of the companies chosen by #eicAccelerator are led by #women, which is an improvement over the previous call, although there is still room for improvement in the gender gap in #leadership positions in our sector. #EUeic #STEMWomen #WomenInBusiness #innovation #SocialImpact

https://lnkd.in/eeBZ9weg VitalDose® EVA Implants for Systemic & Local Delivery of Therapeutics: Cyonna Holmes, PhD, Karen Chen, MS, and Brian Duke explain how systemic delivery approaches that leverage continuous dosing can address adherence issues and improve drug effectiveness while minimizing adverse reactions, and how a localized delivery approach can minimize total drug exposure, reduce off-target toxicities, and overcome targeting issues.

The next wave of biotechs working on weight-loss and cardiometabolic drugs is lining up and raising money to create "triple-G" and non-GLP-1 medicines in the wake of Wegovy and Zepbound's success. The Novo Nordisk and Eli Lilly medications have skyrocketed the field, but their approved treatments leave room for improvement on the side effect and ease-of-access side of things. The latest entrant is Deep Apple Therapeutics, a startup from life sciences VC fund Apple Tree Partners, which is committing $52 million to get its latest bet off the ground and toward the clinic in inflammatory skin conditions, cardiometabolic diseases, migraine and pain, among other areas. #biotech #startup #venturecapital #lifesciences #machinelearning

Could #AI be the answer to more effficient #DrugDiscovery pipelines? Insilico Medicine aims to develop a completely AI-driven drug discovery environment that can dramatically reduce timelines and costs, improve the success rate, and identify more relevant targets and effective drugs for multiple indications. "We realised very early on that we could exploit the field of #GenerativeAI , with the emergence of #GenerativeAdversarialNetworks (GANs) to enable a new approach to AI-based drug discovery," states Alex Aliper, President of Insilico Medicine. https://lnkd.in/esayF-gn

🎙 Up next, Ms. Lydia Bernard-Jones from Sierra Leone. RSVP via this link: https://lnkd.in/dW9u6WUU to hear Lydia speak. 📰Fact checker! Biotech activity in Africa is nascent, but international pharma is tapping into the continent's genetic diversity for clinical trials and therapy development. 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐨𝐧 𝟏𝟔𝐭𝐡 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟒 𝐚𝐭 𝟖 𝐏𝐌 𝐄𝐀𝐓 | 𝟔 𝐏𝐌 𝐖𝐀𝐓 | 𝟓 𝐏𝐌 𝐆𝐌𝐓

Did you miss our recent webinar on "Efficiently Driving Protein-based #NMR Fragment Screening and Lead Discovery" ? Dr. Andrew “Dru” Namanja, Principal Research Scientist at AbbVie, explored the potency ranking methods involving both qualitative single-point ligand concentration (Q Score) and quantitative binding affinity (KD), and how the combined utility can be used successfully to drive a Fragment-Based Drug Discovery (#FBDD) campaign. If you missed any part of it, no worries! You can catch the recorded session here: https://lnkd.in/d9RfpXfs #dataautomation #FragmentBasedDrugDiscovery #Mnova #Mestrelab

Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector). This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/g2UMT3sS #Selatogrel #acutemyocardialinfarction #AMI #P2Y12 #ACT-246475 #buildingblocks 

Thoughts ⭐️ This is why we need more reliable systems for drug development, as well as for novel biomaterial evaluation. 👇🏻 “Out of 367 biomedical therapies tested on animals over thousands of studies, a surprisingly low proportion—only 5%—eventually obtained the approval of the Food and Drug Administration, America’s regulatory agency for drugs, to be used in humans.” . . . . . #bioengineeredtumor #fondzanauku #prizma #cancer #platform #engineering #anticancerdrug #testing #development #3Dmodel #chemicalengineering #biomedicalengineering #research #innovation

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) said it is embarking on a potentially transformational year backed by a €2.89 million grant aimed at building on its research in the realm of longevity. Central to its strategy is the advancement of GF-1002, a promising drug candidate for non-alcoholic steatohepatitis (NASH), now moving towards investigational new drug-enabling stages. At the same time, it is interacting with the European Medicines Agency regarding a novel compound for Werner Syndrome, where sufferers show signs of aging in their 20s.  "While 2023 was a pivotal year, we're poised for an even stronger 2024, as we shift focus to scaling development of our lead drug candidate, GF-1002, and its potential benefits for NASH patients," said chief executive Eric Leire. More at #Proactive #ProactiveInvestors #LSE #OTCQB #GENF #GENFF #GenflowBiosciences #Biotech #Longevity http://ow.ly/q8PQ105eTAX